Latest insights from us
Switchpoint Bio Raises $5.3M Pre-Seed to Make Treatment Response Visible From Blood
Funding advances a blood-based epigenomic platform designed to give drug developers a scalable view into how disease and treatment change human biology.
Switchpoint Bio Joins the Fingenious® Ecosystem
Switchpoint Bio, a company pioneering scalable epigenomic profiling of the immune system, has entered into a partnership with the Fingenious® Ecosystem. The collaboration opens an opportunity to add deep immune biology to research on nationwide Finnish biobank samples, with the aim of improving the diagnosis, monitoring and treatment of diseases. With a single request and a single contract, Fingenious® gives access to all Finnish public biobanks, which together hold more than 14 million samples.
Our Founding Story
From the Founding Story of Switchpoint Bio - “A few years ago, we met again in Cambridge, Massachusetts, and spent an afternoon walking around the Harvard campus. There was no agenda and no company plan, just two old friends talking about science, and about what we wanted to do with the years ahead.”